Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on prostate cancer active surveillance.

"I believe it will be a disruptive technology that fundamentally will change the surgical world for humans and animals," Dr. Wendell Gibby told Newsweek.

The Global Fusion Biopsy Market Size is projected to grow at a CAGR of 8.9% from 2025 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market was ...

MRI, or magnetic resonance imaging ... They use a very thin one in a fine needle biopsy to remove a small sample of cells or tissue. They will use a larger one to get a bigger piece of bone ...

A groundbreaking new scanner developed by scientists at the University of Aberdeen could change the way breast cancer is ...

The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching ...

Multiparametric magnetic resonance imaging (MRI)-based machine learning techniques have the potential to identify B-cell lymphoma-6 (BCL-6) overexpression in patients with primary central nervous ...

The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...

MRI should be considered an adjunct to, and not a replacement for, biopsies for men on active surveillance for prostate cancer. MRI does not consistently rule out the presence of Gleason grade ...